SECURITIES AND EXCHANGE COMMISSION

                   Washington, D.C.  20549


                          FORM 10-Q


     QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE
               SECURITIES EXCHANGE ACT OF 1934

    For Quarter Ended                  March 31, 2000

    Commission file number             33-56574


                        DIASENSOR.COM
   (Exact name of registrant as specified in its charter)



Pennsylvania                                25-1605848
(State of other jurisdiction               (IRS Employer
of incorporation or organization)        Identification no.)


  2275 Swallow Hill Road, Bldg. 2500; Pittsburgh, PA 15220
(Address of principal executive offices)       ( Zip Code)

                       (412) 279-9740
     Registrant's telephone number, including area code

     Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90
days.
                                   Yes   X        No

     As of March 31, 2000, 22,980,051 shares of
Diasensor.com, Inc. common stock, par value $.01 were
outstanding.




<PAGE>1

                               DIASENSOR.COM,INC.
                         (A Development Stage Company)

                          Consolidated Balance Sheets

                                                    March 31,    September 30,
               ASSETS                                 2000          1999
                                                   (Unaudited)
                                                   -----------    -----------
Current assets
  Cash and cash equivalents (note A)               $     4,741    $     6,525
  Prepaid expenses                                       2,638            130
                                                   -----------    -----------
               Total current assets                      7,379          6,655

Property and equipment - at cost(note A)
  Furniture and fixtures                                42,750         42,750
  Less accumulated depreciation                         31,384         28,331
                                                  ------------    -----------
                                                        11,366         14,419
                                                   -----------    -----------

Other Assets
  Due from BICO (note A)                                     -      1,458,809
  Allowance for doubtful account                             -     (1,458,809)
  Investment - MicroIslet,Inc. (note E)                479,167              -
  Investment - Diabecore (note E)                      500,784              -
  Security Deposit                                      17,500         17,250
                                                   -----------     ----------
                                                       997,451         17,250
                                                   -----------     ----------
               TOTAL ASSETS                        $ 1,016,196    $    38,324
                                                   ===========     ==========

               LIABILITIES and STOCKHOLDERS' EQUITY

Current liabilities
  Accounts payable                                 $    12,500     $        -
  Due to BICO                                          435,141              -
  Accrued payroll and withholdings                      91,839         91,214
                                                   -----------    -----------
               Total current liabilities               539,480         91,214

Committments and Contingencies (note A)

Stockholders' equity (deficiency)
  Preferred stock, 1,000,000 shares authorized,
  none issued Common stock, 40,000,000 shares of
  $.01 par value authorized; issued and outstanding
  22,980,051 at Mar. 31, 2000 and 22,980,051 at
  Sep. 30, 1999                                        229,801        229,801
  Additional paid-in capital                        26,892,071     26,892,071
  Warrants                                          18,454,943     18,453,839
  Deficit accumulated during the  development stage(45,100,099)   (45,628,601)
                                                    -----------    -----------
                                                       476,716        (52,890)
               TOTAL LIABILITIES AND               -----------    -----------
                  STOCKHOLDERS' EQUITY             $ 1,016,196    $    38,324
                                                   ===========    ===========
[FN]

  See notes to the financial statements.


                             DIASENSOR.COM, INC.
                     (A Development Stage Company)

<TABLE>
                  Consolidated Statement of Operations
                              (Unaudited)
<CAPTION>
                                            For the six months ended         For the three months ended   From July 5, 1989
                                                    March 31,                          March 31,         (inception) through
                                              2000             1999             2000             1999       March 31, 2000
                                            -------------------------        --------------------------  -------------------
</CAPTION>
<S>                                      <C>              <C>              <C>              <C>            <C>
Research and development expenses         $       -       $      -       $        -        $      -       $ 10,556,405

General and administrative expenses            920,848       242,489          552,966          81,390       14,192,979

Provision for(recovery of)doubtful accounts (1,458,809)          -         (1,093,900)            -              -

Warrant extensions                                -              -                -               -         18,184,986

Technology and patent rights acquired            9,459        49,237            5,675          47,552        2,659,459

Interest expense                                  -            1,499              -             1,499           10,529

Other income                                      -          (26,406)             -           (13,175)        (571,664)

Other expense                                     -              -                -              -              37,405
					    --------------------------	    --------------------------   -------------------
         Net Income (loss)                $    528,502   $  (266,819)    $    535,259    $   (117,266)    $(45,070,099)
                                            ===========    ===========      ===========    ===========   ===================
Net income (loss) per common share        $       0.02   $     (0.01)    $       0.02    $      (0.01)    $      (2.38)
                                            ===========    ===========      ===========    ===========   ===================

See notes to the financial statements.
</TABLE>

<TABLE>
                            DIASENSOR.COM, INC.
                     (A Development Stage Company)

                        Statement of Cash Flows
                              (Unaudited)


<CAPTION>

                                                       For the six months ended   For the three months ended  From July 5,1989
                                                       March 31,      March 31    March 31,        March 31,  (Inception) thru
                                                        2000            1999         2000            1999      March 31, 2000
                                                       ------------------------   --------------------------  ----------------
 <S>                                               <C>             <C>            <C>           <C>           <C>
 Cash flows from operating activities
  Net Income (loss)                                 $    528,502    $  (266,819) $    535,259    $(117,266)   $(45,070,099)
  Adjustments to reconcile net loss to net
   cash used by operating activites:
    Depreciation                                           3,053          3,020         1,527         (342)         78,680
    Amortization of goodwill                              20,833           -           20,833         -             20,833
    Provision for (recovery of) doubtful accounts     (1,458,809)          -       (1,093,900)        -               -
    Impairment loss                                         -              -             -            -             14,367
    Stock in exchange for services                          -              -             -            -            138,950
    Stock issued for License and Marketing Agreement        -              -             -            -             80,000
    Warrants issued for services                           1,104           -             -            -            229,642
    Warrent extensions                                      -              -             -            -         18,184,986
    Inventory deposit-BICO                                  -              -             -            -         (1,000,000)
    (Increase)Decrease in prepaid expenses                (2,508)       (15,221)       (2,638)     (17,210)         (2,638)
    Increase in payable due to BICO                      472,535           -          435,141         -         10,972,535
    Increase (Decrease) in accounts payable               12,500        (12,499)        4,296      (59,935)         12,500
    Increase in accrued payroll and withholdings             625           -              625         -             91,839
    (Increase) in other assets                              (250)          -             (250)        -            (17,500)
                                                      ------------   -----------  ------------  ------------  ----------------
    Net cash used in operating activities               (422,415)      (291,519)      (99,107)    (194,753)    (16,265,905)

Cash flows from investing activities:
 Disposal of property and equipment                         -           175,000          -         175,000         175,000
 Purchase of property and equipment                         -              -             -            -           (279,413)
 Investment - MicroIslet, Inc.                          (500,000)          -         (500,000)        -           (500,000)
 Investment - Diabecore                                 (500,784)          -         (500,784)        -           (500,784)
 Increase in Notes Receivable			            -              -             -	      -           (125,000)
 Increase in Interest Receivable                            -            (5,142)         -          (2,544)        (13,538)
                                                      ------------  ------------  ------------  -------------  ------------
    Net cash used in investing activities             (1,000,784)       169,858    (1,000,784)     172,456      (1,243,735)

Cash flows from financing activities:
 Advances to BICO                                       (437,405)      (176,437)     (436,420)    (151,733)     (7,498,369)
 Repayment of advances to BICO                         1,858,820        283,888     1,530,320      231,523       9,166,099
 Proceeds from issuance of common stock                     -              -              -           -         10,971,834
 Proceeds from issuance of common stock to BICO             -              -              -           -          4,200,000
 Proceeds from warrants exercised                           -              -              -           -            118,066
 Proceeds from treasury stock                               -              -              -           -            (35,000)
 Proceeds from Regulation S                                 -              -              -           -            288,751
 Proceeds from issuance of notes payable                    -              -              -           -            303,000
                                                   --------------  -------------- ------------- ------------  -------------
   Net cash provided by financing activities           1,421,415        107,451     1,093,900       79,790      17,514,381
                                                   --------------  -------------- ------------- ------------  -------------
   Net increase (decrease) in cash and cash equiv.        (1,784)       (14,210)       (5,991)      57,493           4,741
   Cash and cash equivalents at beginning of period        6,525         41,811        10,732        6,285            -
                                                   --------------  -------------- ------------- ------------  -------------
   Cash and cash equivalents at end of period       $      4,741    $    27,601  $      4,741    $  63,778    $      4,741
                                                   ==============  ============== ============= ============  =============

See notes to the financial statements.
</TABLE>





                    DIASENSOR.COM, INC.

         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE A - Basis of Presentation

     The accompanying financial statements of Diasensor.com,
Inc.  (the "Company") have been prepared in accordance  with
generally   accepted  accounting  principles   for   interim
financial information, and with the instructions to Form 10-
Q  and  Rule 10-O Regulation S-X.  Accordingly, they do  not
include  all  of the information and footnotes  required  by
generally   accepted  accounting  principles  for   complete
financial  statements.  In the opinion  of  management,  all
adjustments   (consisting  of  normal  recurring   accruals)
considered  necessary  for  a fair  presentation  have  been
included.   For further information, refer to the  financial
statements  and  footnotes included in the Company's  annual
report on Form 10-K for the fiscal year ended September  30,
1999.

NOTE B - Organization

     The  Company  was incorporated on July  5,  1989  as  a
wholly  owned  subsidiary  of  Biocontrol  Technology,  Inc.
(BICO).   BICO  owns 52% of the stock of the Company  as  of
March  31,  2000.  Diasensor.com is currently  developing  a
noninvasive glucose sensor (Sensor).  The sensor  would  use
electromagnetic   technology  to   measure   blood   without
requiring the user to take a blood sample.

NOTE C - Net Loss Per Common Share

     Net  loss  per  common share is based on  the  weighted
average  number of outstanding common shares which  amounted
to 22,980,051 and 22,980,051 for the periods ended March 31,
2000  and  March 31, 1999, respectively. The loss per  share
does  not include common stock equivalents since the  effect
would be anti-dilutive.

     From  July  5, 1989 (inception) to March 31,  2000,  net
loss per common share is based on the weighted average number
of  common shares outstanding and the number of common shares
issuable  on  the  exercise of 1,708,000 warrants  issued  in
1992;  reduced by 488,000 common shares that were assumed  to
have  been  purchased with the proceeds from the exercise  of
the  warrants  at an assumed price of $3.50 per  share.   The
inclusion  of the warrants in the loss per share  calculation
is  required  by  the  rules of the Securities  and  Exchange
Commission  relative  to  the initial registration  statement
which included the Company's financial statements through the
period  ended  March  31,  1993.  The registration  statement
became  effective July 19, 1993.  The weighted average number
of  common  shares including the effect of the conversion  of
the  warrants amounted to 18,950,660 for the period from July
5, 1989 (inception) to March 31, 2000.




                     DIASENSOR.COM, INC.

   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTE D - Legal Proceedings

     In April, 1998, the Company and its affiliates were
served with subpoenas by the U.S. Attorneys' office; the
Company continues to produce documents and information in
response to such subpoenas.  The class action suit which
names the Company as a defendant remains in the pre-trial
pleading stage pursuant to consent of all the parties.

NOTE E - Investments in Unconsolidated Subsidiaries

     In January 2000, the Company acquired a ten percent
(10%) interest in MicroIslet, Inc. for an investment of
$500,000.  MicroIslet is a California company which has
licensed several diabetes research technologies from Duke
University with a specific focus on optimizing
microencapsulated islets for transplantation.

     In March 2000, the Company acquired an equity interest
in Diabecore Medical, Inc., a Toronto-based company working
to develop a new insulin for the treatment of diabetes, for
$500,784.  With this initial investment, the Company owns
12% of Diabecore, advancing to a 35% ownership at completion
of funding through July 2001.

     Both investments are being reported on the equity basis
and differences in the investment and the underlying net
assets of the unconsolidated subsidiaries is being amortized
as goodwill over a 5 year period.

Management's Discussion and Analysis of Financial Condition
and Cash Flows


Liquidity and Capital Resources

     Cash  decreased from $6,525 at September 30,  1999,  to
$4,741 at March 31,2000.

     As  of  March  31, 2000, amounts due from BICO  to  the
Company was zero, compared to $1,458,809 as of September 30,
1999.   The  decrease was due to BICO's repayment  of  funds
transferred  from  the  Company  to  BICO.   Due  to  BICO's
financial  condition an allowance for doubtful  accounts  in
the  same  amount as the funds due to the Company from  BICO
had  been established in the fiscal year ended September 30,
1999.  Because the full amount was repaid, the allowance for
doubtful accounts was also adjusted in the same amount  from
($1,458,809) to zero.

     As   discussed   in  Note  E,  above,   the   Company's
investments in MicroIslet, Inc. and Diabecore, Inc. occurred
during the quarter ended March 31, 2000.  As a result, these
other assets were $479,167 and $500,784, respectively, as of
March 31, 2000, as compared to zero at September 30, 1999.

     Accounts  Payable increased from zero as  of  September
30,  1999  to  $12,500 as of March 31, 2000.   The  increase
resulted  from  invoices occurring in the normal  course  of
business.   Amounts  due to BICO from the Company  increased
from  zero  as  of  September 30, 1999  to  $435,141.   This
increase is due to intercompany transfers from BICO  to  the
Company  for  working  capital and  to  fund  the  Company's
investments in MicroIslet and Diabecore as discussed in Note
E.

Results of Operations

     There  were no research and development expenses during
the  six month period ended March 31, 2000 and 1999  due  to
the  agreed-upon suspension of billings by Diasensor.com and
BICO pursuant to the research and development agreement.

     General  and  Administrative expenses increased  during
the  second quarter from $81,390 for the three month  period
ended  March 31, 1999 to $552,966 for the three month period
ended March 31, 2000 and increased from $242,489 for the six
month  period ended March 31, 1999 to $920,848 for  the  six
month  period  ended  March 31,  2000.    The  increase  was
primarily  due to an increase in salaries and administrative
staff, along with administrative overhead.

     The  Company  recovered $1,093,900  and  $1,458,809  in
doubtful  accounts  during the three  month  and  six  month
periods  ended March 31, 2000, respectively, as compared  to
no  similar recovery during the prior year's periods.   This
recovery  was  due  to  BICO's  repayments  of  intercompany
transfers,  which  had  been  fully  reserved  as   doubtful
accounts  as  a result of BICO's financial condition  during
the  prior years.

     Because of BICO's repayments of all amounts due to  the
Company,   and  the  corresponding  allowance  for  doubtful
accounts,  as discussed above, the Company's net income  was
$528,502  for  the  six  months ended  March  31,  2000  and
$535,259  for  the  three months ended March  31,  2000,  as
compared to net losses of ($266,819) and ($117,266) for  the
prior year's periods, respectively.

     Other  income during the second quarter decreased  from
$13,175  for the three month period ended March 31, 1999  to
$0  for  the  three month period ended March  31,  2000  and
decreased from $26,406 for the six month period ended  March
31,  1999  to  $0 for the six month period ended  March  31,
2000.  This decrease was due to a reduction in rental income
and  the Company having lower cash reserves to invest during
the  period  ending  March 31, 2000 than during  the  period
ending March 31, 1999.

                PART II -- OTHER INFORMATION

Item 1.   Legal Proceedings
          None.

Item 2.   Changes in Securities
          None.

Item 3.   Defaults Upon Senior Securities
          None.

Item 4.   Submission of Matters to a Vote of Security Holders
          None.

Item 5.   Other Information
          None.

Item 6.   Reports on Form 8-K
          None.

SIGNATURES


     Pursuant to the requirements of the Securities Exchange
Act  of 1934, the registrant has duly caused this report  to
be  signed  on its behalf by the undersigned thereunto  duly
authorized on this 15th day of May, 2000.


                              DIASENSOR.COM, INC.

                              By /s/ Fred E. Cooper
                                     Fred E. Cooper
                                     President and Director
                                     (principal executive officer,
                                     principal financial officer
                                     and principal accounting
                                     officer)